Multiple Indications Equals Tens of Billions in Market Size for Nuvilex, Inc.

Nuvilex, Inc. (OTCQB – NVLX) is no one-trick pony. The Company’s live-cell encapsulation drug delivery platform has already demonstrated that it can significantly improve the efficacy and safety results in mid-stage clinical trial studies in patients in advanced stages of pancreatic cancer. But, as the development progresses, it is not inconceivable that the size of the market for platform reaches the tens of billions worldwide.

On May 8, 2013, Goldman Small Cap Research published an Article on Nuvilex, Inc. (OTCQB – NVLX). For your convenience, a copy of the article can be found below.

Please see previous NVLX reports for relevant disclosures and disclaimer.

Multiple Indications Equals Tens of Billions in Market Size for Nuvilex, Inc.

When reviewing all of the annual revenue generated by the leading pancreatic cancer and chemotherapy treatments, the size of the current market is estimated to be in the $3 billion range, worldwide. Each year, nearly 40,000 patients in the U.S. diagnosed with pancreatic cancer die, making it the fourth-deadliest cancer, and one of the most difficult to treat.

In Phase II clinical trials, Nuvilex’s drug delivery platform has shown remarkable efficacy by activating the anticancer pro-drug ifosfamide in close proximity to the pancreatic cancer itself, and it does so with a high degree of safety. The encapsulation platform’s capability remains high even when the chemotherapeutic agent dosage is two-thirds less than what is typically used, thus enhancing the patients’ quality of life as well. Given the ability to activate pro-drugs and maintain a high degree of safety, Nuvilex management believes that the platform can be used to treat multiple forms of cancer, as evidenced in preclinical studies.

With a market size of at least $10 billion, it is possible that trials to treat breast cancer are next on Nuvilex’s list.

Each year, 230,000 women in the U.S. are diagnosed with breast cancer. Interestingly, some of the FDA-approved treatments for breast cancer are being studied now to treat pancreatic cancer. However, to date, some of these treatments have demonstrated lower efficacy and survival rates in pancreatic cancer patients than with breast cancer patients. Treatments that employ Nuvilex’s cell encapsulation technology have demonstrated greater efficacy, in mid-stage clinical trials in advanced pancreatic cancer, than the current “gold standard” single-agent drug for this disease when compared to historical data for that cancer drug, and have also shown promise in preclinical breast cancer studies. It is possible that the results with breast cancer could ultimately show that the cell encapsulation technology can also be substantially positive, and perhaps even more so, for this indication than they are for pancreatic cancer. Thus, management is extremely optimistic about these prospects.

Plus, since the Nuvilex (OTCQB – NVLX) live-cell encapsulation approach serves as an activator for pro-drugs it is possible that it can be used in conjunction with multiple pro-drugs at the tumor site or even as an alternative early stage defense against rapid tumor progression when used in combination with other treatment modalities such as low-dose radiation. Moreover, as the platform’s efficacy is demonstrated in treating multiple types of cancer, or is used as the activator of multiple pro-drugs, the market for Nuvilex’s encapsulation delivery system could leap from the single digit billions in annual sales to tens of billions worldwide.

This article was paid for by a third party.